Investor Relations Home

Corporate Profile

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system disorders, through proprietary formulations based on existing drugs that are intended to make a significant difference in patients' lives. NeuroDerm currently has four product candidates in development designed to treat moderate to severe Parkinson’s disease. The company designed its product candidates to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration, primarily subcutaneously or transdermally.

Title
Download Documentation NeuroDerm June 2017 Corporate Presentation

Recent News

More >>
DateTitle 
06/08/17NeuroDerm Presents Six Posters at the 21st International Congress of Parkinson’s Disease and Movement Disorders
Includes demographic data from the ND0612 trial 006 and complete data from a Phase 1 pharmacokinetic study of ND0701 REHOVOT, Israel, June 08, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it will present six posters related to its clinical pipeline in a poster session today from 1:15 p.m. to 2:45 p.m. PT at the 21st International Congress of Pa... 
Printer Friendly Version
06/06/17European Medicines Agency Accepts Design of NeuroDerm’s ND0612 Phase III iNDiGO Efficacy Trial
REHOVOT, Israel, June 06, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that it has received a Scientific Advice Letter from the Scientific Advice Working Party of the European Medicines Agency (EMA). The letter accepts the main design elements suggested by NeuroDerm for the amended iNDiGO phase III efficacy trial (trial 007), including study populati... 
Printer Friendly Version
06/05/17NeuroDerm Presents ND0612H Phase II Trial Results in Late-Breaking Poster Session at the 21st International Congress of Parkinson’s Disease and Movement Disorders
-ND0612H achieved a complete reduction of OFF-time to zero in 42% of patients treated for 24 hours - - Statistically significant and clinically meaningful reduction in OFF-time and increase in the portion of patients "ON" by 8:00am- REHOVOT, Israel, June 05, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced final data from trial 006.  Sheila Oren, MD,... 
Printer Friendly Version

Upcoming Events | Past Events

More >>
There are currently no events scheduled.